ASH20 - Allogeen dendritisch celvaccin in fase 2 bij AML

In deze podcast vertelt internist-hematoloog prof. dr. Arjan van de Loosdrecht (Amsterdam UMC) over de resultaten met een van leukemiecellen afgeleid, allogeen dendritisch celvaccin in een fase 2-studie bij patiënten met acute myeloïde leukemie. Hij presenteerde deze resultaten tijdens de virtuele 62ste ASH Annual Meeting.ReferentieVan de Loosdrecht A, et al. ASH 2020: abstr 168.

Episode metadata supplied by the publisher feed · Published Dec 5, 2020

Embed this episode

Attribution link and audio player

Ready to play

ASH20 - Allogeen dendritisch celvaccin in fase 2 bij AML

0:00 16:54

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncologie.nu?

This episode is 16 minutes long.

When was this Oncologie.nu episode published?

This episode was published on December 5, 2020.

Can I download this Oncologie.nu episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!